Phase 3
Completed N=483
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Source: ClinicalTrials.gov NCT02413346 ↗Enrolled (actual)
483
Serious AEs
0.8%
Results posted
May 2018
Primary outcomePrimary: Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) — 94; 94 participants
◆ Published Evidence
Established
29citations · ~4 / year
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study.
Summary
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
Linked Publications
-
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) |
94; 94 | — |
Eligibility Criteria
Inclusion Criteria
- Successfully completed participation in Phase 3 study of sarecycline (SC1401 or SC1402)
- Signed informed consent or assent form
- Body weight between 33 kg and 136 kg, inclusive
- Negative urine pregnancy test for females of childbearing potential
- Agrees to use effective method of contraception throughout study, if applicable.
- Able to fulfill protocol requirements, indicated willingness to participate in study and agrees to all study procedures by providing written informed consent/assent and authorization to disclose (personal health information)
Exclusion Criteria
- Currently participating in another clinical study, unless it is a pharmacokinetic sarecycline study and participation approved by medical monitor; has received investigational medication (except sarecycline) within 30 days of enrollment.
- Discontinued participation in a Phase 3 study with sarecycline for any reason
- Had poor compliance wtih study requirements/study drug dosing in a Phase 3 study with sarecycline
- Is receiving/planning to receive any systemic acne medication, systemic retinoids, systemic corticosteroids or any androgen/anti-androgenic therapy (eg, testosterone, spironolactone)
- Is pregnant, lactating or planning a pregnancy during the study period
- Has a significant intercurrent illness (including clinically significant abnormality in clinical laboratory tests), psychiatric disorder, or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study
- Is judged by the Investigator to be unsuitable for any reason
Data sourced from ClinicalTrials.gov (NCT02413346) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.